Two drugmakers you may have never heard of just agreed to a big deal Irelands Shire says its paying  billion for   which makes a drug to treat a rare condition called   People with the inherited condition are prone to swelling that can be lifethreatening About  in  people have the genetic mutation that causes the problem The deal expected to close in a few months is the latest example of the business allure of highpriced drugs for illnesses that affect a few The prize in the drug companies deal is a medicine called   Derived from human plasma Cinryze is a protein that can prevent swelling attacks About  people in the US have been treated with Cinryze according to Shire CEO Flemming Ornskov Cinryze is pricey A typical treatment requires two vials costing more than  in the US To prevent attacks the treatment is repeated every few days Over the course of a year a persons Cinryze bill can reach hundreds of thousands of dollars making it   Shires biggest seller at the moment is Vyvanse an ADHD pill which brought in nearly  million   But the company also sells Firazyr another drug to treat hereditary angioedema and several others for rare conditions These are the kind of drugs that   is pinning its future on Shires strategy is to focus on speciality medicines and in particular rare diseases Ornskov tells Shots There are thousands of them that dont have effective treatments he says That means there are thousand of opportunities The Food and Drug Administration encourages the development of socalled   which generally are expected to be used by fewer than  people in the US Cinryze is one So too are Shires Elaprase for Hunters syndrome and Vpriv for Gaucher disease On an individual patient level the cost is high for the drugs Ornskov says In actual dollars spent these are relatively small given the size of the patient population He says Cinryze sales should exceed  million this year Sales could increase if more patients are diagnosed and if additional uses are found for the medicine he says As for Cinryzes high price Ornskov says orphan drugs can cost as much to develop as blockbusters for more common conditions Even if they dont the key factor in determining an orphan drugs price is its worth in prolonging life reducing suffering or eliminated the need for other kinds of care Its valuebased he says Its not just mathematical